Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, representing a new class of medicines studied for the treatment of obesity. Tirzepatide is a single peptide that triggers the body’s receptors for GIP and GLP-1, two natural incretin hormones.
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, representing a new class of medicines studied for the treatment of obesity. Tirzepatide is a single peptide that triggers the body’s receptors for GIP and GLP-1, two natural incretin hormones.
The average weight loss with Semaglutide can range from 7 to 14.9% of body weight, depending on the dose and duration of treatment. Many patients lose 60 pounds or more on Semaglutide therapy.
What is the starting dose of Semaglutide for weight loss? All patients start on the lowest dose of Semaglutide at 0.25mgs injected subcutaneously into belly fat every week. All patients increase by 0.25mgs every two weeks as tolerated (slower if nauseous). The dosing being studied for weight loss is 2.5 mg once weekly, which is currently higher than the doses approved in diabetes. Semaglutide is being studied in different populations: people with a body mass index (BMI) greater than or equal to 30 kg/m 2 alone or 27 kg/m 2 with at least one weight-related comorbidity (diabetes excluded).
